BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31955347)

  • 1. Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line.
    Willig JB; Vianna DRB; Beckenkamp A; Beckenkamp LR; Sévigny J; Wink MR; Buffon A; Pilger DA
    Purinergic Signal; 2020 Mar; 16(1):29-40. PubMed ID: 31955347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
    He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
    Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
    Liao HC; Chou YJ; Lin CC; Liu SH; Oswita A; Huang YL; Wang YL; Syu JL; Sun CM; Leu CM; Lin CH; Fu SL
    Biochem Pharmacol; 2019 May; 163():308-320. PubMed ID: 30822403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
    Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE
    Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
    Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW
    Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
    Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
    Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
    Wong SM; Liu FH; Lee YL; Huang HM
    PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
    Wang XY; Sun GB; Wang YJ; Yan F
    Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
    Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of
    Deng Y; Li X; Feng J; Zhang X
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
    Prado-Carrillo O; Arenas-Ramírez A; Llaguno-Munive M; Jurado R; Pérez-Rojas J; Cervera-Ceballos E; Garcia-Lopez P
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells.
    Lan X; Hu M; Jiang L; Wang J; Meng Y; Chen X; Liu A; Ding W; Zhang H; Zhou H; Liu B; Peng G; Liao S; Chen X; Liu J; Shi X
    J Ethnopharmacol; 2023 Jan; 301():115815. PubMed ID: 36220508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
    Giuntoli S; Tanturli M; Di Gesualdo F; Barbetti V; Rovida E; Dello Sbarba P
    Haematologica; 2011 Feb; 96(2):204-12. PubMed ID: 21071498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
    Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.